Novo Nordisk A/S
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
A Study to Look at How Safe NNC0268-0965 is in People With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2019-10-23
- Last Posted Date
- 2022-09-08
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 36
- Registration Number
- NCT04136067
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany
A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (C) Semaglutide Tablets
- First Posted Date
- 2019-09-30
- Last Posted Date
- 2021-02-09
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 278
- Registration Number
- NCT04109508
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Berlin, Germany
A Research Study Comparing a New Medicine Oral Semaglutide to Placebo in People With Type 2 Diabetes
- First Posted Date
- 2019-09-30
- Last Posted Date
- 2023-09-14
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 521
- Registration Number
- NCT04109547
- Locations
- 🇩🇿
Bouzareah Diabetic House Algiers Algeria, Algiers, Algeria
🇩🇿UH of Douera, Algiers, Algeria
🇨🇳The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
A Research Study on How Well Semaglutide Works in Adolescents With Overweight or Obesity
- First Posted Date
- 2019-09-25
- Last Posted Date
- 2024-01-02
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 201
- Registration Number
- NCT04102189
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Southampton, United Kingdom
A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide Tablets
- First Posted Date
- 2019-09-20
- Last Posted Date
- 2022-09-13
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 274
- Registration Number
- NCT04097600
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Berlin, Germany
A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Italy, as Part of Local Clinical Practice
- First Posted Date
- 2019-09-19
- Last Posted Date
- 2023-02-23
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 581
- Registration Number
- NCT04094415
- Locations
- 🇮🇹
Novo Nordisk Investigational Site, Vigevano, Italy
A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in France, as Part of Local Clinical Practice (SURE FRANCE)
- First Posted Date
- 2019-09-10
- Last Posted Date
- 2023-03-28
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 521
- Registration Number
- NCT04083820
- Locations
- 🇫🇷
Novo Nordisk Investigational Site, Yerres, France
Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia With Inhibitors
- Conditions
- Interventions
- First Posted Date
- 2019-09-10
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 136
- Registration Number
- NCT04083781
- Locations
- 🇯🇵
St. Marianna University School of Medicine Hospital_Pediatrics, Kanagawa, Japan
🇯🇵Nara Medical University Hospital_Pediatrics, Nara, Japan
🇯🇵Saitama Medical Univ. Hospital, Saitama, Japan
Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia Without Inhibitors
- Conditions
- Interventions
- First Posted Date
- 2019-09-09
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 158
- Registration Number
- NCT04082429
- Locations
- 🇭🇺
MH Eü. Központ -Orszagos Haemophilia Kozpont, Budapest, Hungary
🇮🇳St. John's Medical college and Hospital, Bangalore, Karnataka, India
🇮🇳Sahyadri Speciality Hospital, Pune, Maharashtra, India
Research Study to Investigate How Well Semaglutide Works Compared to Liraglutide in People Living With Overweight or Obesity
- Conditions
- Interventions
- First Posted Date
- 2019-08-29
- Last Posted Date
- 2023-05-19
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 338
- Registration Number
- NCT04074161
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Olympia, Washington, United States